HBIO / Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q2 2022 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares more_horizontal

HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer more_horizontal

HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended more_horizontal

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from s more_horizontal

Today, we take our first look at medical device concern Harvard Bioscience, Inc. The shares have doubled over the past few months on better-than-expec more_horizontal

The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong more_horizontal

HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer J more_horizontal

Harvard Bioscience's shares are up more than 105% so far this year. The company is seeing strong sales from its equipment to aid in CRISPR gene-editin more_horizontal